Market Overview Artemisinin is a plant derivative isolated from Artemisia annua, or sweet wormwood, which is known to effectively and swiftly reduce the number of Plasmodium parasites in the blood of malaria patients. The WHO recommends artemisinin combination therapies (ACTs) as the first line of treatment for uncomplicated plasmodium falciparum malaria and as the second line of treatment for chloroquine-resistant P. vivax malaria.
Market Dynamics The global artemisinin combination therapy market growth is driven by the rising adoption rate of ACTs coupled with growing government initiatives to combat the malaria epidemic.
The rising prevalence of malaria is expected to drive the growth in the forecast period
Artemisinin combination therapy (ACT) is used for the treatment of plasmodium falciparum malaria. This market has been growing in recent years due to the high prevalence of malaria, especially in developing and under-developing countries. According to the “World Malaria Report 2018” by World Health Organization (WHO), there were an estimated 219 million cases and nearly 435,000 related deaths in 2017 and most of the malaria cases were attributed to Plasmodium falciparum.
Hence the high prevalence of malaria is driving the growth of this market. Other factors like an increase in awareness initiatives by governments and research for new anti-malarial drugs and therapies are also helping this market grow.
Market Segmentation: By Combination Therapy Type • Artemether-Lumefantrine • Artesunate-Amodiaquine • Artesunate-Pyronaridine • Artesunate-Sulfadoxine-Pyrimethamine By End-user • Hospital • Clinics • Research Centers
Geographical Analysis The Middle East and Africa region holds the largest market share global artemisinin combination therapy market
The Middle East and Africa held the largest share in the artemisinin combination therapy market due to the presence of a large production base of artemisinin herbs and rising demand in malaria-endemic countries that are contributing to the growth of the market.
According to the World Health Organization (WHO), there were an estimated 219 million cases of malaria worldwide in 2017, out of which WHO African Region carried a disproportionately high share of the global malaria burden. In 2017, the region contributed 92% of malaria cases and 93% of malaria deaths. The WHO Eastern Mediterranean Region was home for nearly 2% of the global malaria cases. Owing to these factors, the Middle East and Africa region is expected to have one of the largest shares in the artemisinin combination therapy market.
Competitive Landscape The artemisinin combination therapy market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Novartis, Sanofi, Cipla, Ajanta Pharma, Ipca Laboratories, Guilin Pharmaceuticals, and KPC Pharmaceuticals,Mylan N.V,Aspen Holdings,AJANTA PHARMA among others.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the artemisinin combination therapy market globally.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
